Acute Kidney Injury in the Surgical Patient: Recognition and Attribution

Azra Bihorac
Department of Anesthesiology, University of Florida, Gainesville, Fla., USA

Epidemiology of Postoperative Acute Kidney Injury

In the United States, where the average American can expect to undergo 7 surgical operations during her lifetime, each year at least 150,000 patients die and 1.5 million develop a medical complication within 30 days after surgery [1]. In addition to causing a 2-fold increase in 30-day mortality and incurring an annual cost of $25 billion [1, 2], postoperative complications are associated with long-term negative consequences. Postoperative acute kidney injury (AKI), characterized by a decrease in kidney function ranging from a mild decrease in glomerular filtration to complete renal failure, can affect up to 40% of surgical patients. Even if AKI resolves completely, it is associated with increased risks for chronic kidney disease, hemodialysis and death years after surgery [3–11].

Prior to 2004, the reported prevalence of hospital-acquired AKI varied significantly from 1 to 31% due to the incoherent criteria used to define AKI. With the intro-
duction of the AKI definition given by the Risk, Injury, Failure, Loss and End-stage Kidney (RIFLE) consensus, the importance of less severe AKI has been increasingly recognized [12]. The RIFLE guidelines define 3 grades of AKI severity based on at least a 50% change in serum creatinine relative to a reference value [13] and the recent consensus Kidney Disease: Improving Global Outcomes (KDIGO) guidelines have expanded the RIFLE criteria to include creatinine changes as small as 0.3 mg/dl [14]. The implementation of these consensus AKI definitions in the published surgical guidelines has been slow.

The American College of Surgeons Committee on Trauma defines AKI in trauma patients as a rise in serum creatinine above 3.5 mg/dl, but in a multicenter trauma study evaluating prevalence of AKI defined by RIFLE criteria, only 15% of AKI patients had a serum creatinine value greater than 3 mg/dl [5]. The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP), the largest prospective surgical database that quantifies 30-day risk-adjusted surgical outcomes for patients undergoing major surgical procedures [15], defines postoperative AKI as a postoperative rise in serum creatinine greater than 2 mg/dl or as the acute need for renal replacement therapy. To illustrate the lack of sensitivity of such a definition, consider that among patients with normal preoperative kidney function and creatinine in the range of 0.6–1.0 mg/dl, AKI stage-1 (defined by a 50% increase from baseline creatinine) would result in a postoperative serum creatinine change in the range of 0.3–0.5 mg/dl only. For the majority of elderly patients and women, whose baseline creatinine is expected to be ≤0.8 mg/dl, even the most severe stage 3 AKI with a 3-fold increase in postoperative serum creatinine would result in <1.6 mg/dl change from baseline, and thus would remain below the NSQIP cutoff of 2 mg/dl. Two large studies using the ACS NSQIP data sets reported very low AKI prevalence, ranging between 1 and 1.6%, with an 8-fold increase in 30-day mortality [16, 17]. In a single-center cohort study of over 20,000 surgical patients, comparison between the NSQIP and consensus definitions for AKI demonstrated that NSQIP captured only 7% of patients with AKI defined by consensus criteria. After applying the RIFLE definition to the 97% of patients with no AKI by NSQIP criteria, an additional 35% of the patients in the cohort were identified as having AKI and had a 5-fold increase in mortality compared to those with no AKI. Eighty percent of all 90-day postoperative deaths occurred among patients with RIFLE AKI, although most of them had mild to moderate AKI only [3]. More importantly, the risk-adjusted association between change in postoperative serum creatinine and various adverse clinical outcomes is continuous, and the complex association between magnitude and recovery of renal function plays a further role in determining the outcomes of patients with AKI [18]. The future studies in surgical population will need to address the issue of AKI staging among patients with very low baseline creatinine (<0.6 mg/dl) when urine output data is not available [19, 20]. Contrary to the belief that postoperative AKI is a rare and fatal complication for which not much can be done in surgical patients, emerging evidence implies that AKI is a common and serious postoperative complication associated with increased risk for short and long-term mortality, other postoperative complications, resource utilization and cost (table 1) [3, 4, 21]. Increased awareness of the significance of AKI and the implications of not acting to prevent AKI in high-risk patients, or to facilitate renal recovery in established AKI, are costly and unacceptable.

### Risk Stratification for Postoperative AKI

The risk for any postoperative complication, including AKI, arises from the interactions between a patient’s preoperative health and her physiologic capacity to withstand surgery-related stress, modulated by the type and quality of surgery that the patient undergoes. Knowing the extent to which preoperative health status predispos-

---

**Table 1. Risk-adjusted increase in hospital cost and mortality associated with postoperative AKI**

<table>
<thead>
<tr>
<th>AKI stage</th>
<th>Risk-adjusted relative cost ratio (95% CI)</th>
<th>Risk-adjusted relative mortality ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with no AKI</td>
<td>1 (reference)</td>
<td>1 (reference)</td>
</tr>
<tr>
<td>Patients with any AKI</td>
<td>1.59 (1.57–1.61)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.38 (2.00–2.84)&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>RIFLE-R</td>
<td>1.44 (1.42–1.46)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.71 (1.41–2.08)&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>RIFLE-I</td>
<td>1.88 (1.84–1.91)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.33 (1.90–2.84)&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>RIFLE-F</td>
<td>2.57 (2.51–2.63)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>5.53 (4.52–6.77)&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup> p value <0.001 using generalized linear models to compare with the non-AKI group. Adopted from Hobson et al. [21].

---

AKI in the Surgical Patient

Nephron 2015;131:118–122

DOI 10.1159/000439387

Downloaded by: University of Florida, Gainesville and Jacksonville
es a patient to the development of postoperative complications can facilitate a discussion between the patient and her physicians regarding the risks and benefits of surgery, and can decrease a patients’ anxiety and uncertainty regarding outcomes. In the preoperative period, physicians need accurate risk assessment for AKI to timely identify those patients with the highest potential to benefit from protective therapies. Some of these therapies are not only costly but carry their own risks, like intraoperative goal-directed therapy or invasive hemodynamic monitoring.

The modification of intraoperative management appears to have an important effect on kidney function. A recent meta-analysis of 20 randomized controlled trials of perioperative hemodynamic monitoring identified several interventions that were associated with significant reduction in the incidence of all severity stages of AKI [22]. Optimizing intravascular volume, cardiac output or oxygen delivery in high-risk patients (those having emergency surgery, those with a higher revised cardiac risk index or a higher risk according to criteria of the American Society of Anesthesiologists and those aged >60 years) resulted in a decreased risk of perioperative AKI, both if started preoperatively (OR 0.70, 95% CI 0.53–0.94; p = 0.02) or intraoperatively (OR 0.47, 95% CI 0.27–0.81; p = 0.006). Future studies related to the effects of intraoperative goal-directed therapy for AKI prevention are warranted. Other less costly interventions are easy and reasonable to implement if the risk is identified, like avoiding nephrotoxic contrast media and non-steroidal anti-inflammatory medications in patients with chronic kidney disease, and avoiding anesthetic techniques that may contribute to hemodynamic instability in high-risk patients [23]. All of these interventions are either often applied without consideration of a patient’s preoperative risk or not applied at all because the risk is underestimated [24].

In the postoperative period, a patients’ preoperative risk is modulated by their response to the events of surgery, often manifesting as subtle changes in physiologic parameters like blood pressure or heart rate. The physician’s intraoperative management of hemodynamic status, sedation and mechanical ventilation directly affects surgery-related stress and can either exacerbate it or ameliorate it. With dynamic measurement of the risk for AKI, there will be the opportunity to initiate timely and appropriate preventive therapies, such as appropriate goal-directed fluid resuscitation and monitoring in the intensive care unit, for those patients who are judged to be at high risk.
risk of AKI. Similarly, if risk for AKI is judged to be low, patients may avoid exposure to unnecessary procedures and therapies.

Most of the studies for preoperative AKI risk stratification have been limited to a specific type of surgery or have used the occurrence of severe or dialysis-dependent AKI as an end point while excluding the more prevalent mild to moderate AKI. Studies on patients undergoing cardiac surgery reported predictive models for severe AKI with area under the receiver operating characteristic curve (AUROC) values up to 0.84 [25, 26]. Among patients undergoing non-cardiac surgery data is limited to predictive scores for severe AKI only with the AUROC below 0.77 [16, 27].

The myriad of continuous physiologic data routinely acquired during intraoperative monitoring is rarely used in published risk scores and, when used, is usually summarized using a reductionist approach (such as mean or lowest value) rather than applied in their continuity and is almost never collected and analyzed in real time. With the advance of electronic health records, the ability to utilize the richness of clinical data collected as a part of routine care for the development of new diagnostic tools is dramatically increased. Novel approaches using machine learning algorithms based on automated, rapid, noninvasive measurements of cardiorespiratory physiology obtained in the operating room and intensive care unit will be applied to a range of risk prediction tasks to improve patient care and resource allocation. Using the readily available demographic, socioeconomic, comorbidity, intraoperative, laboratory and medication data, we have developed a computerized algorithm that calculates a probabilistic risk score for postoperative AKI defined by consensus criteria. The risk score ranged from 0 to 1, with a high score indicating a high risk of AKI. The model had good performance with an overall AUROC of 0.87, and 2 cutoff points (0.3 and 0.5) were used to identify those patients with low, medium and high risk for AKI. For patients with a preoperative risk score for AKI ≥0.5, the odds for developing postoperative AKI were 28 times higher (95% CI 27–30) compared to patients with a lower risk score of <0.3 (fig. 1) [24]. Future studies will require large data sets and prospective validation of this approach before clinical use.

A recently validated urinary biomarker for AKI, TIMP2 (tissue inhibitor of metalloproteinase 2 and insulin-like growth factor binding protein 7) test, provides a new tool to assess the risk of AKI in postoperative patients [28, 29]. Patients with a urinary TIMP2*IGFBP7 level of >0.3 ng/ml (2/1,000) had 7 times the risk for developing moderate to severe AKI within 12 h of the test compared to patients with urinary TIMP2*IGFBP7 level of <0.3. This is the first urinary biomarker approved by the US Food and Drug Administration for risk stratification of AKI in critically ill patients (NephroCheck® Test, Astute Medical, Inc., San Diego, Calif., USA). Although these studies did not specifically test postoperative patients, high-risk surgery and trauma were considered as risk factors for AKI allowing the inclusion of a significant proportion of surgical patients in both cohorts. The adequate identification of surgical patients who should undergo urinary (TIMP2*IGFBP7) test is critical, and validation of clinical risk stratification tools for this purpose is of great importance.

In summary, AKI significantly affects perioperative outcomes. AKI is a common complication after surgery, and mild to moderate AKI is more common than severe AKI. All stages of AKI severity are associated with increased short- and long-term morbidity and mortality. Clinical risk factors for AKI are similar but not identical in different surgical populations. Current strategies should focus on better management of the preoperative risks and susceptibilities for AKI and those intraoperative hemodynamic derangements that have been shown to impact renal function.

Acknowledgments

A.B. is supported by Center for Sepsis and Critical Illness Award P50 GM-111152 from the National Institute of General Medical Sciences and has received research grants from Society of Critical Care Medicine and Astute Medical, Inc.

References


AKI in the Surgical Patient

Nephron 2015;131:118–122
DOI 10.1159/000439387


